A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Pheon Therapeutics
Takeda
Tempus AI
Alaunos Therapeutics
Black Diamond Therapeutics, Inc.
Mirati Therapeutics Inc.
Peter MacCallum Cancer Centre, Australia
Mayo Clinic
Mirati Therapeutics Inc.
NantCell, Inc.
ADC Therapeutics S.A.
HiberCell, Inc.
pharmaand GmbH
MacroGenics
University Health Network, Toronto
Case Comprehensive Cancer Center
CureOne
National Institutes of Health Clinical Center (CC)
Helsinn Healthcare SA
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
Cota Inc.
Masonic Cancer Center, University of Minnesota
New York State Psychiatric Institute
Cornerstone Pharmaceuticals
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Stanford University
National Cancer Institute (NCI)
Calando Pharmaceuticals
National Cancer Institute (NCI)
Auron Healthcare GmbH
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Massachusetts General Hospital
Cancer Research UK
Vanderbilt-Ingram Cancer Center